<DOC>
	<DOCNO>NCT02190838</DOCNO>
	<brief_summary>Treatment disseminate melanoma still difficult issue . Obvious achievement recent year prove efficacy immunologic approachees field . The ability melatonin metformin decrease metabolic immunosuppression show many experimental study . Some literature data confirm possibility increase efficacy melatonin dacarbazine ( DTIC ) metformin DTIC combination . We hypothesize combination could effective DTIC monotherapy term response rate time progression .</brief_summary>
	<brief_title>Comparison Melatonin Metformin Dacarbazine Combination Versus Dacarbazine Alone Disseminated Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Age &gt; 18 . Obtained Inform Consent Morphologically confirm disseminated Stage IV melanoma Eastern Collaborative Oncology Group Performance Status Scale 0 2 . Expected survival &gt; 3 month Evidence active brain lesion ( brain lesion stereotaxic ray therapy allow ) Evidence liver bone marrow clinically meaningful disfunction Severe uncontrolled concomitant condition diseases Pregnancy lactation Systemic therapy disseminate melanoma Second malignancy Diabetes mellitus require drug therapy Any condition preventing study participation investigator opinion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Melanoma</keyword>
	<keyword>Melatonin</keyword>
	<keyword>Metformin</keyword>
	<keyword>Dacarbazine</keyword>
</DOC>